Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study.

Cancer medicine - 1 Nov 2020

Hendrickson Peter G, Luo Yukun, Kohlmann Wendy, Schiffman Josh, Maese Luke, Bishop Andrew J, Lloyd Shane, Kokeny Kristine E, Hitchcock Ying J, Poppe Matthew M, Gaffney David K, Tao Randa

Abstract excerpt

BACKGROUND: Li-Fraumeni Syndrome (LFS) is a rare cancer-predisposing condition caused by germline mutations in TP53. Conventional wisdom and prior work has implied an increased risk of secondary malignancy in LFS patients treated with radiation therapy (RT); however, this risk is not well-characterized. Here we describe the risk of subsequent malignancy and cancer-related death in LFS patients after undergoing RT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Germ-Line Mutation
Share to Li-Fraumeni Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Neoplasms, Radiation-Induced

Share to Neoplasms, Second Primary

Share to Radiotherapy

Share to Registries

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 32931654
DOI: 10.1002/cam4.3427
PMCID: PMC7643676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study.PMID 32931654Read ↗

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.Semantic proximity Read ↗

Multiple Primary Cancers in Families With Li-Fraumeni SyndromeSemantic proximity Read ↗

Risk of multiple primary cancer diagnosis over age in families of Li-Fraumeni syndrome: a single institution perspectiveSemantic proximity Read ↗

Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni SyndromeSemantic proximity Read ↗

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriersSemantic proximity Read ↗

Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.Semantic proximity Read ↗

Inherited TP53 Mutations and the Li-Fraumeni Syndrome.Semantic proximity Read ↗

Li-Fraumeni Syndrome: Imaging Features and GuidelinesSemantic proximity Read ↗

A matched case-control study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome (BREAST TP53).Semantic proximity Read ↗

The Li-Fraumeni syndrome.Semantic proximity Read ↗

Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.Semantic proximity Read ↗

Hematologic malignancies in Li-Fraumeni syndrome: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.